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Abstract
Infection with Staphylococcus aureus does not induce long-lived protective immunity for reasons 
that are not completely understood. Human and murine vaccine studies support a role for 
antibodies in protecting against recurring infections, but S. aureus modulates the B cell response 
through expression of Staphylococcal Protein A (SpA), a surface protein that drives polyclonal B 
cell expansion and induces cell death in the absence of co-stimulation. In this murine study, we 
show that SpA altered the fate of plasmablasts and plasma cells (PCs) by enhancing the short-lived 
extrafollicular response and reducing the pool of bone marrow (BM)-resident long-lived PCs 
(LLPCs). The absence of LLPCs was associated with a rapid decline in antigen-specific, class-
switched antibody. In contrast, when previously inoculated mice were challenged with isogenic 
Δspa S. aureus, cells proliferated in the BM survival niches and sustained long-term antibody 
titers. The effects of SpA on PC fate were limited to the secondary response, as antibody levels 
and the formation of B cell memory occurred normally during the primary response in mice 
inoculated with either WT or Δspa S. aureus. Thus, failure to establish long-term protective 
antibody titers against S. aureus was not a consequence of diminished formation of B cell 
memory; instead, SpA reduced the proliferative capacity of PCs that entered the BM, diminishing 
the number of cells in the long-lived pool.
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Introduction
Staphylococcus aureus is a major cause of hospital and community acquired infections and 
has become more difficult to treat as antibiotic-resistant strains spread (1). S. aureus 
infections commonly recur without inducing long-term immunity (2) and despite the success 
of some vaccine approaches at inducing short-term protection in mouse models, attempts to 
design a human vaccine have failed (3–5). Studies in humans and mice have correlated pre-
existing serum antibody (Ab) and passive immunization with improved clinical and 
experimental outcomes (6–10). Mutations that reduce Ab production also increase the risk of 
acquiring S. aureus infections (5). Further, a recent study reported that maintenance of 
antigen-specific Ab during convalescence correlated with reduced recurrence of infection 
(11). Despite this evidence that B cells can play a role in protection against S. aureus, little is 
known about the long-term humoral response to S. aureus.
Staphylococcus Protein A (SpA) is a virulence factor released from S. aureus during normal 
cell division allowing soluble and processed antigens to activate the immune system (12, 
13). SpA activates B cells upon binding the Fab portion of B cell receptors (BCRs) of the 
VH3 clan (up to 50% of naïve B cells in humans and 5–10% in mice) inducing robust non-
specific B cell response (14–16). SpA sequesters IgG by binding the Fc portion and 
interferes with immune complex (IC)-mediated antigen presentation and phagocytosis (17, 
18). This suggests that the expression of SpA on S. aureus alters the B cell response to 
infection.
Memory B cells and long-lived plasma cells (LLPCs) confer long-term humoral immunity. 
Serum Ab levels are sustained by LLPCs derived mainly from memory B cells activated 
during secondary immune responses (19–21). Memory B cells have been identified after 
infection with viral, parasitic, and bacterial pathogens (22–25), but whether these cells are 
formed after S. aureus infection has not been directly addressed. Memory B cells reside in 
an inactive state in secondary lymphoid organs, and upon re-exposure to antigen, rapidly 
divide into daughter cells or differentiate into antibody secreting cells (ASCs), which include 
surface Ig positive dividing plasmablasts (PBs) and the more mature, non-dividing surface 
Ig− plasma cells (PCs) (26). Though the majority of PBs and PCs are short-lived, some 
migrate to survival niches in the bone marrow (BM), proliferate, and mature into LLPCs (19, 
21, 27). Niche factors, including APRIL, support PB proliferation, and PC differentiation 
and survival (28–30). LLPCs and their constitutively secreted Ab are recognized as major 
contributors to protection against bacterial infection (31–33). In mice, LLPCs can survive 
the lifetime of an organism while in humans, they can survive for months to decades, and are 
the main source of convalescent serum IgG (20, 34, 35). It remains unclear whether LLPCs 
are formed after S. aureus infection, or whether SpA influences long-term B cell memory or 
LLPCs.
In this study, we show that SpA disrupts the proliferation of PBs in the BM and subsequent 
accumulation of LLPCs, while promoting expansion of short-lived PBs in the spleen. Mice 
previously inoculated and then challenged with a SpA-deficient S. aureus mutant (Δspa), but 
not with WT S. aureus, formed LLPCs and maintained serum Ab for at least 12 weeks after 
challenge. The lack of long-term humoral immunity to WT S. aureus was not due to defects 
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in memory B cell formation or activation because primary inoculation with either WT or 
Δspa induced the formation of germinal centers (GC) and functional memory B cells. 
Rather, SpA altered the differentiation of ASCs during the secondary response by expanding 
IgM+ extrafollicular PBs, and reducing the proliferative capacity and the expression of the 
survival receptor, CD138 on PBs that entered the BM, thereby diminishing their ability to 
enter the LLPC pool.
Materials and Methods
Mice
C57BL/6 mice were bred and maintained in a specific pathogen-free facility at UNC Chapel 
Hill according to the Institutional Animal Care and Use Committee standards. At 7–8 weeks 
of age, mice were inoculated subcutaneously (sc) with 1 × 108 colony forming units (CFUs) 
of S. aureus RN4220 (Δspa or WT), Newman, or USA300 in 20 μl of 1x PBS. For challenge 
experiments, 5 weeks after primary inoculation, 1 × 106 CFU were delivered intravenously 
(iv) via tail vein injection in 100 μl of 1x PBS. For NP-KLH experiments, 100 μg of 
NP20KLH conjugated to alum (Imject) was delivered by intraperitoneal injection (ip). 
Immunized mice were boosted (iv) with 100 ug of soluble NP20KLH.
Bacteria
S. aureus RN4220 (Δspa and WT), Newman and USA300 were grown in brain heart 
infusion (BHI) broth at 37°C overnight and washed and diluted in 1x PBS for inoculations. 
CFUs were confirmed by plating serial dilutions on BHI plates. Isogenic S. aureus Δspa 
mutants (Newman and RN4220) were constructed by amplifying ≈ 1 kb homology 
fragments flanking spa with primers Spa5′.1A (CGACTCTAGAGGAAAAACACACTTC) 
and Spa5′.1B (TAAGGATCGGGGACAATACCTACACC) for amplification of the 5′ 
homology fragment and primers Spa3′1A (TACCGAGCTCGAATATCATTTTATCC) and 
Spa3′1B (CAGTGCAGCGGAATTGCTTGGAGTCC) for amplification of the 3′ homology 
fragment. The resulting fragments were cloned on either side of a Specr cassette in the E. 
coli/S. aureus shuttle vector pBT2ts. Allelic exchange was performed as previously 
described (36) and confirmed by sequence analysis. To confirm spa deletion, genomic DNA 
was purified from RN4220 WT, RN4220 Δspa::erm, Newman WT, and Newman Δspa::erm. 
Primers flanking spa were used to amplify across the genomic region around and containing 
spa and result in ≈ 2.1 kb fragments in WT strains and ≈ 1.7 kb fragments in strains where 
spa has been deleted and replaced by erm. Primers for amplification across spa: Spa.2A: 5′ 
TTACGCAAGTGTGCTGTATTC Spa.2B: 5′ AACAAAAGATGTTGCTCGTGC. S. aureus 
ΔsrrAB mutants in RN4220 and Newman were generated as previously described (36).
Real-Time PCR
RNA was purified from log phase (O.D. ≈ 1.0) S. aureus by mixing 25 ml of culture with 25 
ml of Ethanol/Acetone (1:1). Samples were incubated at −80° C overnight, centrifuged and 
remaining cell pellets were lysed using Lysing Matrix B (MP Biomedicals, Solon, OH) and 
bead beater. RNA was purified from lysed cells using the PurLink RNA mini kit (Invitrogen, 
Carlsbad, CA) following the manufacturers instruction. Quantitative real-time PCR was 
carried out using the SensiFAST SYBR and Fluorescein One-step kit (Bioline, Taunton, 
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MA) following manufacturer instructions. The S. aureus housekeeping gene rpoD was used 
to normalize spa transcript between strains. Primers: rpoD_RT1.A: 5′ 
AACTGAATCCAAGTGATCTTAGTG rpoD_RT1.B: 5′ 
TCATCACCTTGTTCAATACGTTTG spa_RT.1A: 5′ GTAGGTATTGCATCTGTAAC 
sap_RT.1B: 5′ TTGAGCTTCATCGTGTTGCGC
Kidney burden analysis
To assess the bacterial load in kidneys, 7–8 week-old C57BL/6 mice were infected (iv) with 
1 × 106 CFU of S. aureus Newman or RN4220 WT, Δspa, or ΔsrrAB. Kidneys were 
harvested 5, 7 or 14 days later. Kidneys were homogenized in 1x PBS and serial dilutions of 
homogenate were plated on BHI. CFUs were counted after overnight incubation at 37°C.
ELISA
For S. aureus ELISAs, vinyl plates were coated overnight at 4°C with S. aureus RN4220 
Δspa grown to stationary phase, washed, and diluted 1:10 in 1x PBS. Plates were blocked 
with 0.5% bovine serum albumin (BSA) overnight at 4°C. Samples were loaded in 0.5% 
BSA and incubated overnight at 4°C, then incubated with anti-IgG, anti-IgG2, or anti-IgM 
conjugated to alkaline phosphatase for 1 hour at 37°C and developed with p-nitrophenyl 
phosphate. For IsdB ELISAs, polystyrene plates were coated with 3 μg/ml IsdB (AA40-614) 
in carbonate buffer overnight at 4° and blocked in 0.5% BSA for 1 hour at 37°C. Plates were 
loaded and developed as for whole S. aureus ELISAs. For ClfA ELISAs, polyvinyl plates 
were coated with 10 μg/ml ClfA in PBS overnight at 4° and blocked in 0.5% BSA for 1 hour 
at 37°C. Plates were loaded and developed as for whole S. aureus ELISAs.
Antibody-mediated macrophage opsophagocytosis assay
GFP-expressing RN4220 (Alexander Horswill, Carver College of Medicine) were incubated 
with heat-inactivated sera (1% of total reaction) for 10 minutes at room temperature, then 
incubated with RAW 264.7 macrophages (MFs) at a ratio of 1:15 with rotation at 37° for 20 
minutes. After incubation, MFs were treated with trypsin, washed with cold PBS, and fixed 
in 4% paraformaldehyde. The mean fluorescent intensity of GFP in each sample was 
determined by flow cytometry.
Flow cytometry
Spleens or lymph nodes were crushed into single cell suspensions in cold 1x PBS. Bone 
marrow cells were harvested from femurs by flushing with 1x PBS. Cells were washed and 
red blood cells (RBCs) lysed with 0.165M NH4Cl. 106 cells per sample were labeled with a 
live/dead dye and Fc receptors blocked with 2.4G2 before Ab staining. Lymphocytes and 
monocytes were identified by forward and side-scatter profiles. GC B cells were identified 
as CD19+ GL7+ FAS+; Tfh cells as CD4+ PD-1+ CXCR5+; ASCs as CD138+ B220lo/neg; 
DCs as CD11chi CD19− CD3− CD49b− Ter119− and CD8α+ or CD8α−; pDCs as CD11c+ 
CD19− CD3− CD49b− Ter119− CD45RA+; eosinophils as Siglec-F+ CD11bint. For 
intracellular cytokine analysis, cells were fixed and permeabilized (BD Biosciences) 
overnight at 4°C before staining. For intracellular IL-12, cells were incubated for 3 hours at 
37°C with 3 ug/ml Brefeldin A before fixing. For chemokine receptor analysis, cells were 
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labeled in azide-free buffer at 37°C, then washed in normal buffer on ice to halt recycling. 
Data for DC analyses were collected on a Becton Dickinson LSR II and analyzed with 
FlowJo. All other samples were run on a Beckman Coulter CyAn ADP and analyzed with 
Dako Summit.
Antibodies and reagents
Abs specific for CD19, CD3e, CD4, PD-1, APRIL, CD11c, IL-12p40, Ter119, CD11c, 
MHCII IA/IE, TACI were purchased from Biolegend; GL7, FAS, CXCR5, CD138, B220, 
IgG, Siglec, CD19, CD8, CD45RA, Annexin V, and Streptavidin-HRP from BD 
Biosciences; GR-1, CXCR4, CD3e, CD49b, CD40, CD86, CD80 from eBiosciences; 
BCMA from R&D Systems. IgM (B7.6) and anti-Fc (2.4G2) were purified from 
hybridomas. Live/Dead Pacific Orange, Fixable Blue dyes, anti-IgG-Alkaline Phosphatase, 
anti-IgM- Alkaline Phosphatase, Streptavidin were purchased from Invitrogen/Life 
Technologies; SDF-1 from Shennendoah Biotechnology; anti-IgG2- Alkaline Phosphatase 
from Southern Biotech; p-Nitrophenyl Phosphate tablets, 3-amino-9-ethylcarbazole tablets, 
PNA-biotin, and lipopolysaccharide from Sigma; anti-IgGFc from Jackson Immunoresearch; 
Brefeldin A from LC Laboratories. IsdB peptide (AA 40-613) was a gift from Dr. Benfang 
Lei (Montana State University). Pokeweed mitogen was a gift from Dr. Shane Crotty (La 
Jolla Institute for Allergy & Immunology).
ELISpot for ex vivo ASC analysis
Multiscreen ELISpot plates were coated with 1.5 μg/ml IsdB (AA40-613) or NP13BSA in 1x 
PBS overnight at 4°C and blocked in 1% BSA overnight at 4°C. Single cell suspensions of 
RBC-lysed splenocytes or BM cells were plated at 0.5–2 × 106 cells/well for 18 hours and 
spots developed with anti-IgG or IgM as previously described (37).
ELISpot for memory B cells
Spleens and lymph nodes were harvested and single cell suspensions were washed and 
RBC-lysed. Cells were plated at 0.5 × 106 cells/ml 1:1 with irradiated (1200 rad) feeder cells 
and cultured with 5 μg/ml LPS, 1:10,000, and 1:1000 fixed S. aureus for 5 days at 37°C. 
After 5 days, cells were washed and plated in serial densities (0.25–2 × 106 cells/well) on 
IsdB-coated ELISpot plates and developed as above.
Tissue immunofluorescence and microscopy
Spleens were fixed in 4% paraformaldehyde for 5hrs at RT, washed with PBS, hardened in 
30% sucrose overnight, and then washed and flash frozen in OCT (Tissue-Tek). Sections (6 
microns) were fixed in 1:1 MeOH/acetone and blocked in 0.5% rat serum and 2.4G2 before 
staining for B220-Alexa647 and IgM-biotin/streptavidin-488 to detect extrafollicular foci. 
To detect GCs, fixed sections were blocked in 10% FBS and 2.4G2 and stained with B220-
Alexa647 and PNA-biotin/streptavidin-488. Sections were imaged with an Olympus 
Fluoview 500 (10x objective; numerical aperture of 0.45) and analyzed using ImageJ.
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Migration assays
Splenic B cells were purified by negative selection (Stem Cell Technologies), and 5 × 106 
cells were plated in the top chamber in a 5 μm trans well insert (Corning). For control wells, 
cells were plated in the bottom chamber with no insert. 100 ng/ml of CXCL12/SDF-1 was 
added to the bottom chambers and plates were incubated for 3hr at 37°C. Samples from the 
bottom and control wells were harvested and labelled with CD138 and B220 and 
enumerated by flow cytometry for 120 seconds per sample. The number of migrated ASCs 
enumerated from the bottom of the trans well was divided by the number enumerated from 
the corresponding control well and expressed as a percent of ASCs in the control well.
In vivo proliferation assay
Inoculated and challenged mice were injected (ip) with 2 mg BrdU (Sigma) in PBS on day 
10 post-challenge (day 45). After 2 hours, BM cells were harvested and BrdU-labelled ASCs 
were identified by flow cytometry according the BD Pharmingen BrdU Flow Kit protocol.
Results
S. aureus Protein A interferes with the accumulation of bone marrow plasma cells
To assess whether S. aureus induces the formation of LLPCs, and whether this is impacted 
by Protein A (SpA), we subcutaneously (sc) inoculated mice with strain RN4220 expressing 
SpA (WT), or an isogenic spa deletion mutant (Δspa) (Figure 1A and Supplemental Figure 
1A). We chose sc inoculation because clearance of S. aureus could be readily monitored at 
the injection site within 3 weeks. We used the sub-infectious strain, RN4220, because its low 
virulence allowed mice to be analyzed over a long period of time without significant weight 
loss or morbidity, while still inducing a localized skin infection and a S. aureus-specific Ab 
response. SpA did not change the frequency of B cells in nearby peripheral lymph nodes 
(PLNs) after sc infection (Supplemental Figure 1B). Total S. aureus-specific serum IgG and 
IgG2 were detectable between 2 and 5 weeks after primary inoculation with either S. aureus 
Δspa (1.5-fold over naïve) or WT (2-fold over naïve) (Supplemental Figure 1C and D), 
indicating that our model results in a productive primary B cell response in the presence or 
absence of SpA.
Most LLPCs are derived from PBs and PCs (hereafter referred to collectively as ASCs) that 
have taken up residence in the BM within 2 weeks after activation of memory B cells (19, 
20). Therefore, we measured the frequencies of ASCs (defined as CD138+/B220lo/neg) in the 
BM 35 days after inoculation and periodically for 2 weeks following a second intravenous 
(iv) inoculation (herein referred to as challenge) (Figure 1A). ASCs appeared in the BM by 
day 40 (day 5 post-challenge), regardless of whether mice were challenged with WT or Δspa 
S. aureus; however, after on day 45 (day 10 post-challenge) their frequency began to decline 
in the WT, but not Δspa-challenged mice (Figure 1B). This was not due to an inability to 
migrate toward the BM niche, since ASCs that formed after WT challenge migrated through 
a trans-well membrane towards CXCL12 (Supplemental Figure 1E), and expressed similar 
levels of CXCR4 (Supplemental Figure 1F). The frequencies of total ASCs continued to 
increase in the BM of Δspa-challenged mice for 2 weeks at which point they were 
significantly higher than those measured in WT-challenged mice (Figure 1B). This 
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phenotype was not unique to RN4220, as mice infected and challenged with the clinical 
strain Newman displayed significantly more BM ASCs 2 weeks after challenge with Δspa 
Newman compared to WT Newman (Figure 1C). Few ASCs were observed in the BM after 
primary inoculation (Figure 1B), consistent with studies showing that higher numbers of 
BMPCs are formed during secondary responses (20, 38). In contrast to the BM phenotype, 
the frequency of splenic ASCs on day 40 (day 5 post-challenge) was significantly higher in 
WT- compared to Δspa-challenged mice (Figure 1D). No significant differences were 
observed after day 42 (day 7 post-challenge) when the frequency of ASC began to decline. 
Therefore, the presence of SpA in the challenge inoculation enhances the splenic ASC 
response and simultaneously disrupts the accumulation of ASCs in the BM.
IgG Abs specific for the S. aureus cell surface hemoglobin receptor IsdB have been detected 
in infected mice and have recently been studied in vaccine trials (39, 40). To compare the 
numbers of S. aureus-specific ASCs in WT and Δspa challenged mice, we performed 
ELISpots using IsdB as a target antigen. We observed significantly more IsdB-specific IgG 
ASCs in the BM of mice challenged with Δspa compared to WT S. aureus (Figure 1E), 
indicating the response is specific to S. aureus. In the spleen, IsdB-specific ASCs were 
found in slightly higher numbers after WT challenge, although this difference was not 
statistically significant (Figure 1F). Together, these data indicate that primary and early 
secondary S. aureus-specific Ab responses are not quantitatively enhanced in the absence of 
SpA. These findings are consistent with a previous study (41), but contrary to a study 
showing that primary iv infection with SpA-deleted S. aureus (Newman) enhances the 
production of Abs to select antigens (42).
S. aureus Protein A does not affect memory B cell responses
The significantly higher numbers of IsdB-specific ASCs observed in the BM 14 days after 
challenge (day 49) compared to 14 days after primary inoculation is consistent with a 
memory B cell response (Figure 1E). ASCs that migrate and persist within survival niches in 
the BM are most often derived from activated memory B cells (19, 43). Therefore, a defect 
in the early memory responses could have disrupted accumulation of BM ASCs after WT 
challenge. To test this, we used ELISpot to detect the numbers of IsdB-specific memory B 
cells after in vitro polyclonal stimulation. On day 35 post-inoculation, ex vivo lymphocytes 
from the spleens and lymph nodes were activated with pokeweed mitogen. The 6-day culture 
period is too short to induce class-switch; thus, all antigen-specific IgG-secreting cells 
detected by ELISpot are derived from memory B cells (22, 23). We detected significantly 
greater numbers of memory-derived ASCs in both Δspa and WT-inoculated compared to 
naïve mice, regardless of whether SpA was present (Figure 2A). Consistent with this, we 
found that germinal center (GC) B cells, which are required in the formation of high-affinity 
memory B cells (44), were present after inoculation in the draining lymph nodes and spleen, 
and appeared with similar kinetics in both WT and Δspa infected mice (Figures 2B–C). T 
follicular helper cells (Tfh), which are required for GC development (45) were also induced 
at similar frequencies after primary inoculation with S. aureus Δspa or WT (Supplemental 
Figure 1G).
Keener et al. Page 7
J Immunol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Memory B cells could be reactivated because secondary IgG2 (IgG2a, 2b, and 2c) responses 
were more rapid and robust 2 weeks post-challenge compared to a primary responses to the 
same stimuli (2–6 fold; Figure 2C) (46, 47). This increase was also apparent in total IgG 
(Supplemental Figure 1H), and dependent on a previous inoculation as indicated by the 
significantly higher levels of IgG2 and IgG compared to primary inoculation (iv) of naïve 
mice (Figure 2D and Supplemental Figure 1I). In addition, we found that challenge with 
either WT or Δspa S. aureus induced early amnestic IgG responses to IsdB (Figure 2E), 
which were also dependent on previous inoculation (Figure 2F). To ensure that the 
secondary response was not unique to RN4220, we inoculated and challenged mice with the 
clinical strains, Newman and USA300. We observed enhanced secondary responses similar 
to those induced by RN4220 (Figure 2G). Memory to S. aureus was long-lived since mice 
were able to produce amnestic S. aureus-specific Ab responses (2–3 fold) when challenged 
100 days after primary inoculation (Supplemental Figure 1J).
It was recently shown that when SpA is neutralized during infection, mice produce a more 
diverse Ab repertoire (48). Thus, despite Δspa-challenged mice making fewer total splenic 
ASCs than WT-challenged mice, it is possible they developed better Ab diversity, which 
would enhance ex vivo opsonization. We found that heat-inactivated serum from both Δspa 
and WT challenged mice facilitated phagocytosis of GFP+ S. aureus; however, sera from 
Δspa challenged mice resulted in enhanced internalization (Figure 2H). Together these data 
indicate that the lack of accumulation of BM ASCs in WT-challenged mice is not caused by 
defects in B cell memory formation, or the immediate memory response. Rather, inoculation 
with S. aureus induces memory B cells that respond to challenge by making functional Ab, 
which is more effective when produced in the absence of SpA.
The presence of Protein A during challenge expands plasmablasts in the spleen
Although mice challenged with WT S. aureus (day 35) made significantly more splenic 
ASCs (day 40) than those challenged with Δspa (Figure 1D), both groups produced similar 
levels of Abs against S. aureus surface proteins in the first 2 weeks after challenge (Figure 
2). Both WT and Δspa-challenged mice also displayed similar frequencies of ASCs in the 
BM for the first 10 days after challenge (Figure 1B). To understand why splenic ASCs 
induced during WT challenge didn’t promote a more robust humoral response, we examined 
them in greater detail during the peak (day 40) of secondary ASC response (Figure 3A). We 
found that the expansion of ASCs in WT-challenged mice was not due to changes in the 
frequency of B cells (Supplemental Figure 2A), but was due to increases in CD138+/
B220lo/neg cells (Figure 3B and 3C). Compared to naïve mice given S. aureus as a primary 
inoculation, mice challenged (iv) with either WT or Δspa S. aureus had a higher frequency 
and total number of ASCs (Figure 3C and Supplemental Figure 2B) and produced 2–6 times 
more IsdB-specific IgG-secreting ASCs compared to naive mice given a primary inoculation 
on the same day (Figure 3D). This is consistent with reactivation of memory B cells. In 
contrast with the frequency of total ASCs, the number of IsdB-specific ASCs was not altered 
by the presence of SpA, consistent with our findings that short-term secondary IgG 
responses were similar between WT and Δspa challenged mice (Figure 2). These data 
suggest that SpA promotes expansion of total ASCs, but not ASCs specific for the S. aureus 
surface antigen, IsdB.
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SpA has previously been identified as a B cell superantigen that binds the VH3 class of 
BCRs and drives polyclonal B cell expansion and apoptosis (49). Since IgM binds SpA with 
a higher affinity than IgG (50), we reasoned that if SpA induced the expansion of ASCs by 
binding Fabs of VH3 BCRs, the ASC population would contain a large fraction of PBs 
retaining surface IgM. We found that 54% of the ASCs formed after WT challenge were 
surface IgM-expressing PBs, compared to only 30% of ASCs formed after Δspa challenge 
(Figure 3E). The frequency of IgG-expressing PBs was not significantly different between 
the two groups (20.5% of Δspa and 17.8% of WT) (Figure 3F). These data suggest that most 
of the surface Ig+ PBs expanded by SpA during WT challenge were IgM+ cells that did not 
result in greater levels of S. aureus-specific serum IgM, or increased numbers of IsdB-
specific IgM+ ASCs (Supplemental Figure 2C and 2D). This is consistent with previous 
observations that SpA+ S. aureus can drive non-specific PB proliferation without inducing 
Ab secretion (51).
Since the loss of SpA reduces bacterial virulence and colonization of the kidney (52), it is 
possible that the reduced expansion of IgM+ PBs during Δspa challenge reflects reduced 
virulence of the Δspa mutant. S. aureus lacking the virulence factor SrrAB displays a defect 
in virulence comparable to Δspa (Supplemental Figure 3A). Loss of srrab did not disrupt 
expression of spa (Supplemental Figure 3B), allowing us to test the effect of SpA on the 
expansion of ASC and migration to the BM apart from its effects on bacterial burden. We 
challenged mice with RN4220 WT, Δspa, or ΔsrrAB and found both WT and ΔsrrAB 
expanded ASCs and IgM+ PBs to levels observed after WT challenge (Supplemental Figure 
3C and D). Thus, the lack of expansion of IgM+ PBs in Δspa-challenge mice was not caused 
by reduced virulence, but by the absence of SpA.
In models of autoimmunity, sepsis, or chronic inflammation, aberrant expansion of short-
lived ASCs has been shown to disrupt the establishment and retention of a LLPC population 
(53–58). We found that accumulation of BM ASCs was defective in mice challenged with 
ΔsrrAB 14 days earlier (Supplemental Figure 3E), and by 14 days post-challenge, no 
bacteria were found in the kidneys of mice from any group (data not shown). These data 
demonstrate that virulence or ongoing infection did not cause the observed defect in BM 
ASC accumulation after WT challenge. Rather, the absence of SpA reduces the expansion of 
extrafollicular IgM+ PBs and allows BM ASCs to accumulate.
Protein A induces expansion of short-lived extrafollicular plasmablasts in the spleen
Short-lived ASCs typically divide in the extrafollicular space of lymphoid organs (38). In 
WT-challenged mice, the transient elevation of IgM+ ASCs suggests SpA induces short-
lived cells that cannot survive long-term in the BM. To assess this, we analyzed spleen 
sections on day 40 (day 5 post-challenge) and found that compared to Δspa, WT-challenged 
mice induced larger and more frequent extrafollicular foci composed of IgM+/bright cells 
(Figure 4A). These foci were located in the splenic red pulp (4A arrows) and the bridging 
channels adjacent to B cell follicles (Figure 4A asterisks). The expansion of extrafollicular 
foci coincided with a significant increase in the frequency of DCs producing IL-12, a 
cytokine that promotes ASC differentiation (59, 60) (Supplemental Figure 3F).
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It is possible that the expansion of short-lived extrafollicular ASCs occurs at the expense of 
GC formation (53, 61). This could reduce the pool of ASCs selected for long-term survival 
in the BM since post-GC PCs likely have a selective advantage once they reach the BM (62). 
We found that at the peak of the ASC response, the frequency of GC B cells was not reduced 
in WT-challenged mice compared to Δspa-challenged mice (Figure 4B). Instead, mice 
challenged with WT S. aureus produced GC B cells at higher frequencies than those 
challenged with Δspa, and both groups displayed similar GC kinetics as the secondary 
response resolved (Supplemental Figure 4A). By microscopy, we observed that GC 
structures of similar sizes were formed after Δspa and WT challenge at similar frequencies 
(Supplemental Figure 4B and data not shown). Thus, the diminished number of BM ASCs 
following WT-challenge was not caused by a GC defect.
Protein A diminishes proliferation and CD138 expression of bone marrow ASCs
The inability of ASCs to accumulate in the BM following WT challenge (Figure 1B) could 
be due to defective migration, the death of ASCs in the BM, or a lack of ASC proliferation 
in the BM. ASCs arrive in the BM at similar frequencies between days 40 and 45, regardless 
of whether SpA is expressed during challenge (Figure 1B), and migration toward CXCL12 
and expression of CXCR4 were not affected by SpA (Supplemental Figure 1E and F). Thus, 
the inability of WT-challenged mice to accumulate BM ASCs could be due to an 
inhospitable BM niche. Systemic inflammation depletes BM niche factors like eosinophils 
and APRIL that are required for LLPC survival (29, 57, 63), so we assessed whether ASCs 
with specificity other than S. aureus could populate the BM during WT or Δspa S. aureus 
inoculation. We immunized mice with (4-hydroxy-3-nitrophenyl)-acetyl hapten conjugated 
to Keyhole limpet hemocyanin (NP-KLH), and 35 days later boosted with NP-KLH alone, 
or boosted and co-infected (iv) with S. aureus RN4220 WT or Δspa. We detected similar 
numbers of NP-specific IgG ASCs in the BM on day 49 (day 14 post-boost), regardless of 
whether mice were co-infected with S. aureus WT or Δspa (Figure 5A). This suggests that iv 
inoculation with WT S. aureus does not disrupt the competence of the BM to support ASCs. 
In support of this, we found that the frequencies of eosinophils and APRIL+ BM cells were 
similar between WT and Δspa-challenged mice (Figure 5B–C). These data suggest that the 
defect in ASC accumulation after WT S. aureus challenge was not caused by a disruption in 
the BM niche environment, but by an alteration intrinsic to the ASC population.
To determine which cell-intrinsic characteristics were responsible for the lack of 
accumulation of ASCs in the BM, we measured cell surface expression of the receptors on 
ASCs that detect BM niche factors (TACI, BCMA, and CD138) (28, 64, 65). Although 
ASCs from Δspa and WT-challenged mice displayed similar levels of TACI and BCMA 
between days 10 and 12 post-challenge (days 45 and 47) (Supplemental Figures 4C and D), 
ASCs from Δspa-challenged mice expressed significantly higher levels of CD138, a 
maturation marker and receptor for APRIL (Figure 5D). Although APRIL levels in BM cells 
were unaffected by SpA (Figure 5C), the diminished expression of CD138 might limit the 
ability of ASCs (formed after WT challenge) to detect APRIL, a niche factor that provides 
both proliferation and survival signals in the BM niche.
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ASCs that migrate to the BM must proliferate to fill the BM niche and compete for survival 
factors necessary to become LLPCs (27). To determine whether these requirements were 
defective in ASCs from WT challenged mice, we measured the frequencies of dividing and 
apoptotic ASCs in the BM between days 10 and 12 post-challenge. Similar frequencies of 
ASCs from WT and Δspa-challenged mice expressed the apoptotic marker Annexin V 
(Supplemental Figure 4E), suggesting that cell death is not responsible for the inability of 
ASCs to become LLPCs in the BM of WT-challenged mice. To assess proliferation of BM 
ASCs, we intraperitonealy (ip) injected mice with BrdU on day 10 post-challenge (day 45). 
After two hours, we examined BM ASCs and found that more ASCs from Δspa-challenged 
mice had incorporated BrdU compared to ASCs from WT-challenged mice, indicating that 
more cells had undergone DNA synthesis (Figure 5E). Thus, after their arrival in the BM, 
ASCs that formed in the presence of SpA are defective in their ability to proliferate, which 
may prevent them from occupying the BM niche.
Secretion of antigen-specific IgG by LLPCs is disrupted following challenge with WT S. 
aureus
To test the long-term impact of diminished proliferation after WT challenge, and to confirm 
that ASCs were not simply delayed in arriving to the BM, we measured IsdB-specific ASCs 
8 weeks after challenge (day 91). BM ASCs induced by Δspa challenge were maintained for 
8 weeks, indicating they had established a pool of LLPCs; however, the low numbers of 
ASCs present 2 weeks after WT challenge (day 49) remained unchanged at 8 weeks post-
challenge (Figure 6A). Although BM is the main site of LLPC survival, the spleen also 
harbors PCs for a significant period of time (66). We examined whether expanded ASCs 
induced by WT challenge could persist in the spleen over time. The numbers of ASCs 
present in the spleen declined in both WT and Δspa-challenged mice by week 8 post-
challenge, to levels that were not different from those in naïve mice (Figure 6B). This 
indicates that WT challenge did not establish LLPCs in the spleen.
The function of LLPCs is to maintain antigen-specific Abs for long periods of time as an 
early defense during re-exposure to pathogens (31, 32). We observed that short-term, the S. 
aureus-specific IgG responses in the first 2 weeks after challenge with WT or Δspa were 
similar (Figure 2). Since we could not detect significant numbers of antigen-specific BM 
ASCs in WT-challenged mice, we hypothesized that this Ab response would not be 
maintained beyond two weeks. To test this, we measured serum IgG in groups of WT- or 
Δspa-challenged mice bi-weekly for 12 weeks after challenge. We found that by 4 weeks 
post-challenge the levels of IsdB-specific IgG diverged; mice challenged with Δspa S. aureus 
maintained relatively high serum Ab for the 12-week period, while the serum Ab levels in 
mice challenged with WT S. aureus dropped to levels detected in uninfected mice (Figure 
6C). We observed a similar divergence in the Ab response to a different S. aureus protein, 
ClfA, at 12 weeks post-challenge (Figure 6D) as well as in mice infected and challenged 
with Newman strains (Figure 6E). This drop in antigen-specific Ab is consistent with the 
decreased frequency of antigen-specific ASCs in the BM (Figure 1B). Importantly, the 
differences in Ab production we observed between WT and Δspa-challenged mice at 10 and 
12 weeks post-challenge were not due to differences present early in the secondary response. 
Therefore, although the presence of SpA during a challenge inoculation does not disrupt the 
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formation of memory B cells and secondary ASC responses, it impairs the accumulation of 
BM ASCs coincident with decreasing proliferation and expression of CD138, and prevented 
long-term maintenance of antigen-specific serum IgG.
Discussion
S. aureus infections commonly recur without inducing protective immunity. Whether this 
relates to an inability to form or activate memory B cells, or defects in establishing establish 
LLPCs in the BM has remained unclear. In this study, we show that SpA caused short-lived 
extrafollicular PBs to expand and dominate the secondary humoral response within the 
spleen. In addition, the expression of SpA during challenge infection diminishes the 
proliferation of ASCs that enter the BM, thereby decreasing the LLPC pool, and 
consequently, long-term Ab production. These findings identify a previously unappreciated 
mechanism by which SpA disrupts the formation of LLPCs, a critical event in sustaining Ab 
titers.
Our findings demonstrate a reciprocal relationship between short-lived ASCs and LLPCs. In 
cases of infection, chronic antigen exposure promotes splenic short-lived ASC proliferation 
over BM PC by altering chemokine production and responsiveness (57). Similarly, in a 
model of systemic lupus erythematosus, chronic availability of autoantigen disrupts the 
responsiveness of splenic ASCs to CXCL12, coincident with an inability of diseased mice to 
generate BM PC (66). Our study shows that migration and homing of ASCs to the BM were 
normal following S. aureus infection, suggesting that the mechanism that links splenic ASC 
expansion to reduced LLPC numbers in S. aureus infection is unique.
Expanded numbers of splenic ASCs and reduced numbers of BM PCs are also evident in 
immunized Fcγ−/− mice (60). This phenotype is accompanied by an increase in the numbers 
of IL-12+ DCs. IL-12 has been demonstrated to enhance T-independent B cell responses (59) 
and because the frequency of IL-12-producing DCs is increased after WT, but not Δspa 
challenge it is possible that SpA-induced IL-12 may enhance T-independent B cells 
responses during S. aureus infection. For example, during challenge infection with WT S. 
aureus, the ability of SpA to bind Fc regions of IgG might impede immune complex-FcγR 
interactions. The absence of FcγR activation would result in a net increase of DCs 
producing IL-12 in response to TLR ligands on S. aureus (60, 67, 68). In turn, this would 
induce a preference toward short-lived extrafollicular ASCs over LLPC.
The altered fate of LLPCs after challenge with SpA+ S. aureus may also be controlled at the 
level of transcription. Previous work showed that lowering the threshold of B cell activation 
through loss of the transcription factor Aiolos increases proliferation of short-lived splenic 
ASCs and diminishes the number of LLPCs in the BM, without affecting GCs, BM niche 
factors, or chemokine homing (69). This is much like the phenotype we observed in mice 
challenged with SpA+ S. aureus. This raises the possibility that SpA ligation of the BCR 
might alter transcription factors involved in LLPC proliferation or survival.
The ASCs formed after challenge with SpA-deficient S. aureus were more likely to 
proliferate upon reaching the BM (Figure 5E). This phenotype was coincident with an 
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increase in the levels of CD138, a marker of maturity and a receptor for the ASC survival 
factor, APRIL (65, 70). Together, these data are consistent with a model of “imprinted” 
LLPC fate, in which some ASCs differentiating in the spleen receive BCR- or T cell-derived 
signals that induce a pattern of gene expression required to become a LLPC in the BM (71, 
72). In this model, ASCs expanded by SpA in extrafollicular spaces (Figure 4A) would be at 
a disadvantage because they may be less likely to receive T cell help. Alternatively, they may 
lack the appropriate BCR signals required to upregulate CD138, or other as-yet-undefined 
receptors necessary for BM niche survival. This scenario would be similar to infection with 
Plasmodium chabaudi which drives an expanded T-independent ASC response while 
inhibiting long-term maintenance of the T-dependent Ab response (53). The fact that most of 
the expanded ASCs induced by SpA were surface IgM+ may also be important if the genes 
expressed during formation of LLPC are downstream of BCR signaling through IgG, but not 
IgM (73). Another possibility is that the expanded short-lived ASCs induced by SpA 
occupied vital BM niches long enough that properly “imprinted” ASCs missed a window of 
opportunity to become established in the long-lived pool. There is evidence that such a 
window is controlled by transient expansion and activation of chemokine-producing BM 
niche cells (74). This may explain why the numbers of LLPCs in WT S. aureus-challenged 
mice failed to catch-up to those observed in Δspa-challenged mice several weeks after the 
splenic ASC response resolved (Figure 6A).
Our finding that challenge with SpA+ S. aureus promotes an expansion of IgM+ PBs has two 
important implications. First, the expansion is not accompanied by an increase in total serum 
IgM or in IgM-producing IsdB-specific ASCs, consistent with previous studies showing that 
SpA promotes non-specific PB proliferation without inducing Ab secretion (51). This ability 
of SpA to regulate IgM+ ASCs might have implications during the LLPC response since 
IgM-FcμR interactions are required for PC trafficking to the BM after T-dependent 
immunization (75). FcμR negatively regulates T-independent B cell responses in the spleen 
(75, 76). Therefore, the ability of SpA to increase IgM+ ASC numbers without an 
accompanying increase in secreted IgM could indirectly interfere with the establishment of 
the LLPC compartment. Second, the expansion of IgM+ PBs after challenge with SpA+ S. 
aureus suggests a significant contribution of IgM memory B cells in addition to activation of 
naïve cells. Changes in gene expression allow memory B cells to divide more rapidly 
compared to naïve B cells (47). Memory B cells also express higher levels of co-stimulatory 
molecules and TLRs (77). Thus, the effects of SpA may preferentially target the memory 
population since SpA-BCR binding increases TLR2 sensitivity, resulting in ASC 
proliferation without Ab production (51). In addition, SpA mediates BCR-mediated uptake 
of S. aureus, leading to the activation of intracellular TLRs (78). Further, IgM memory B 
cells are more often positioned within the marginal zone compared to IgG memory cells. 
Their preferred presence in the marginal zone, where exposure to soluble SpA may be 
enhanced, may also favor short-lived extrafollicular responses (47, 61, 79). Flow-based 
methods to detect S. aureus-specific memory B cells will allow future studies to discern the 
respective roles of memory B cell subsets in infection (80).
Secondary B cell responses to SpA+ S. aureus are unable to contribute to pathogen clearance 
(41, 81–83). The underlying mechanisms have remained unclear; however, it was found that 
abscess formation is decreased when SpA is neutralized (39, 84) or when mice are first 
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vaccinated with a mutant form of SpA that cannot bind the Fab or Fc portions of Ab 
(SpAkkaa) (48). These studies implicate SpA in failed protective immunity. Our study 
provides mechanistic evidence that SpA disrupts sustained production of Ab by preventing 
the accumulation of LLPCs. Although we could achieve sustained convalescent Ab levels 
through vaccination with SpA-deficient S. aureus, this strategy does not confer protection 
upon challenge with SpA-expressing S. aureus because SpA manipulates memory responses 
by altering BCR-mediated responses and sequestering IgG that might otherwise participate 
in preventing or clearing the infection. We confirmed this by challenging previously infected 
mice, and then re-challenging (3rd infection) with WT Newman S. aureus (106 CFUs) 14 
weeks later. We found that despite the sustained production of Ab after a second infection 
with SpA-deficient S. aureus, the third infection with SpA+ S. aureus resulted in bacterial 
organ burdens similar to those sustained by mice with no convalescent Ab (mice who 
received a second infection with WT S. aureus) (data not shown). This occurred despite the 
Ab being functional in vitro (Figure 2H). This suggests that the convalescent levels of 
protective Ab are not adequate to prevent abscess formation in this model. It is important to 
point out that murine protection studies with S. aureus are complicated by the need to use a 
burden of bacteria that greatly exceeds levels found in human sepsis (typically 104–105 
bacteria/ml blood). Thus, it is possible that convalescent Ab in mice might be sufficient if a 
more physiologic bacterial burden could be used in assessing protection. Regardless of this 
limitation in S. aureus challenge models, our study shows that SpA impedes the continued 
production of Ab by preventing the accumulation of LLPCs, in addition to its earlier role in 
sequestering existing Ab.
Thus, our data show that S. aureus infection can generate B cell memory. Despite this, the 
presence of SpA during a subsequent infection drives an excess of short-lived PBs that do 
not enhance the S. aureus-specific Ab levels, but rather hinder LLPC production. This data 
may have implications for vaccines as they suggest that infection with SpA-expressing S. 
aureus can manipulate the B cell response and hinder long-lived humoral immunity even if 
memory has been successfully established. It would be interesting to test the effect of the 
SpAkkaa vaccine on the accumulation of LLPC and long-term Ab levels. This could provide 
insight into whether antibodies against SpA are sufficient to attenuate the negative effects of 
SpA on the LLPC population during challenge infection.
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Figure 1. ASCs fail to populate the bone marrow after challenge with Protein A (SpA+) WT S. 
aureus
(A–B, D–F) Mice were inoculated (sc) with S. aureus RN4220 WT or Δspa and challenged 
35 days later with S. aureus RN4220 Δspa or WT. (A) Schematic of inoculation and 
challenge course. (B) CD138+ B220lo/neg ASCs from the BM were quantitated by flow 
cytometry on the indicated days. n=5 experiments, 3–12 mice/time point. (C) Mice were 
inoculated (sc) with S. aureus Newman Δspa and challenged 35 days later with S. aureus 
Newman Δspa or WT. Frequency of BM ASCs was measured on day 49 (day 14 post-
challenge). n=2 experiments, 5–7 mice/group. (D) The frequency of splenic ASCs at the 
indicated time points. n=7 experiments, 3–13 mice/time point. (E–F) Anti-IsdB IgG-
producing ASCs quantitated by ELISpot from (E) BM and (F) spleens on day 49 (day 14 
post-challenge). Data represent (E) 7 experiments, 3–14 mice per group and (F) 10 
experiments, 5–12 mice per group. Differences in B–D were determined by a Mann Whitney 
test; for B time points were compared independently. E and F were compared using one-way 
ANOVA. *p<0.05, **p<0.01, ***p<0.001 n.s.=not significant. Error bars=standard error of 
the mean.
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Figure 2. Memory B cells are formed and activated in response to S. aureus
(A–H) Mice were inoculated (sc) with S. aureus RN4220 WT or Δspa. (A) Memory B cells 
detected by ELISpot 35 days post-inoculation. Data represent 3 experiments, 6–8 mice per 
group. (B) Frequencies of GC B cells in draining PLNs or spleens at indicated time points. 
Data represent 4 experiments, 3–6 mice per group per time point. (C–F) Primed or naïve 
mice were challenged (iv) with S. aureus RN4220 WT or Δspa on day 35. S. aureus-specific 
(C and D) IgG2 or (E and F) IsdB-specific IgG measured by ELISA from sera collected on 
the indicated days. Sera for D and F were collected on day 14 post-challenge (day 49 for 
primed mice). Data represent (C) 7 experiments, 9–21 mice per group, (D) 3 experiments, 5–
18 mice per group, (E) 10 experiments with 5–16 mice per group, (F) 3 experiments, 9–12 
mice per group. (G) S. aureus-specific serum IgG from mice inoculated (sc) with S. aureus 
RN4220, Newman, or USA300 and challenged with the same strain 35 days later. Data 
represent 3 experiments, 3–8 mice per group. (H) Mean fluorescence intensity (MFI) of 
GFP-expressing S. aureus after in vitro phagocytosis by macrophages in the presence or 
absence of day 49 serum harvested from mice infected and challenged as in A. Data 
represent 4 experiments, 2–8 mice per group. O.D.=optical density. Groups in A, C, and E 
were compared using a Mann Whitney test; D and F using one-way ANOVA; H using an 
unpaired t test. *p<0.05, **p<0.01, n.s.=not significant. Error bars=standard error of the 
mean.
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Figure 3. SpA induces the expansion of IgM+ plasmablasts
(A) Schematic of inoculation and challenge course. (A–F) Mice were inoculated (sc) with S. 
aureus RN4220 WT or Δspa. On day 35, primed and naïve mice were challenged (iv) with S. 
aureus RN4220 WT or Δspa. Spleens were harvested for analysis 5 days later (day 40). (B) 
Representative flow cytometry histograms of ASC analysis in (C). (C) Compilation of the 
frequency of ASCs from (B). Data represent 7 experiments, 2–13 mice per group. (D) Anti-
IsdB IgG-producing ASCs quantitated by ELISpot. n=4 experiments, 4–9 mice/group. (E–F) 
Frequency of surface (E) IgM+ and (F) IgG+ ASCs measured by flow cytometry. n=4 
experiments, 3–9 mice/group. Groups in C–F using one-way ANOVA. FS=forward scatter; 
SS=side scatter; *p<0.05, **p<0.01, ***p<0.001, n.s.=not significant. Error bars=standard 
error of the mean.
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Figure 4. SpA drives an expanded extrafollicular response
(A–B) Mice were inoculated (sc) with S. aureus RN4220 Δspa, and challenged (iv) 35 days 
later with S. aureus RN4220 Δspa or WT. (A) Day 40 spleen sections labeled with B220 
(blue) and IgM (green) to image extrafollicular foci. n=3 experiments, 5–6 mice/group. 
Arrows indicate foci and * indicates bridging channels. Full image scale bar=300 microns, 
inset scale bars=100 microns. (B) The frequencies of splenic GC B cells measured on day 40 
(day 5 post-challenge). n=2 experiments, 2–5 mice/group. Groups in B were compared using 
a Mann Whitney test. n.s.=not significant. Error bars=standard error of the mean.
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Figure 5. The presence of SpA during challenge induces defects in the proliferation of bone 
marrow ASCs and the expression of CD138
(A) Mice were immunized with NP20KLH by i.p. injection and 35 days later boosted with 
soluble NP20KLH alone or co-infected (iv) with S. aureus RN4220 Δspa or WT. On day 49 
(day 14 post-boost/inoculation), NP-specific IgG-producing ASC were quantitated by 
ELISpot. n=2 experiments, 2–6 mice/group. (B–E) Mice were inoculated (sc) with S. aureus 
RN4220 Δspa and challenged 35 days later with S. aureus RN4220 Δspa or WT. (B–C) The 
frequency of (B) eosinophils and (C) APRIL-producing cells present in BM on day 40 (day 
5 post-challenge). n=3 experiments, 3–6 mice/group. (D) MFI and representative flow 
cytometry histograms of CD138 on BM ASCs on days 45 and 47 (days 10 and 12 post-
challenge). n=3 experiments, 6–10 mice per group. (E) Frequency of BrdU+ BM ASCs on 
day 10 post-challenge (day 45). n=2 experiments, 6 mice/group. Groups in A were 
compared using one-way ANOVA; B–C using a Mann Whitney test; for D and E, an 
unpaired t test was used. *p<0.05, n.s.=not significant. Error bars=standard error of the 
mean.
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Figure 6. SpA prevents long-term maintenance of bone marrow LLPCs and serum Ab
(A–D) Mice were inoculated (sc) with S. aureus RN4220 Δspa and challenged 35 days later 
with S. aureus RN4220 Δspa or WT. (A–B) Anti-IsdB IgG-producing ASCs quantitated by 
ELISpot from the (A) BM and (B) spleens of challenged mice on days 49 and 91 (day 14 
and 56 post-challenge). n=3 experiments, 3–6 mice/group. (C) IsdB-specific IgG measured 
by ELISA from sera collected on indicated time points after challenge. n=5 experiments, 4–
10 mice/group. (D) ClfA-specific IgG measured by ELISA from sera collected 12 weeks 
post-challenge (day 119). n=4 experiments, 5–6 mice per group. (E) Mice were inoculated 
(sc) with S. aureus Newman Δspa then challenged 35 days later with S. aureus Newman WT 
or Δspa. IsdB-specific IgG was measured by ELISA from sera collected 14 weeks post-
challenge (day 133). n=3 experiments, 4–8 mice/group. Differences in A–E were determined 
by a Mann Whitney test; for C time points were compared independently. OD=optical 
density, *p<0.05, n.s.=not significant. Error bars=standard error of the mean.
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